PARP1 and hyperinsulinemic hypoglycemia, familial, 4: However, several studies have reported that certain cancers without a BRCA deficiency have significant clinical benefits to PARP1 inhibitors positing that PARP inhibitors could be expanded to a target population beyond BRCA-deficiency (e.g., gBRCA mutation carriers) [18,19,20,21].